# Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

> **NCT05705492** · PHASE2 · RECRUITING · sponsor: **OHSU Knight Cancer Institute** · enrollment: 66 (estimated)

## Conditions studied

- Advanced Malignant Solid Neoplasm
- Advanced Biliary Tract Carcinoma
- Advanced Esophageal Carcinoma
- Metastatic Esophageal Carcinoma
- Locally Advanced Colorectal Carcinoma
- Locally Advanced Esophageal Carcinoma
- Locally Advanced Gastric Carcinoma
- Metastatic Colorectal Carcinoma (mCRC)
- Advanced Lung Carcinoma
- Locally Advanced Hepatocellular Carcinoma

## Interventions

- **DRUG:** Olanzapine
- **DRUG:** Placebo Administration
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT05705492
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-17
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-01-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05705492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05705492, "Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05705492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*